img

Global Immune Checkpoint Inhibitors Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Immune Checkpoint Inhibitors Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
Immune Checkpoint Inhibitors report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Immune Checkpoint Inhibitors market is projected to reach US$ 36030 million in 2034, increasing from US$ 12550 million in 2022, with the CAGR of 16.1% during the period of 2024 to 2034. Demand from Lung Cancer and Colorectal Cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Immune Checkpoint Inhibitors industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Immune Checkpoint Inhibitors key manufacturers include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine and Junshi Biosciences, etc. Bristol Myer Squibb, AstraZeneca, Merck are top 3 players and held % sales share in total in 2022.
Immune Checkpoint Inhibitors can be divided into PD-1/PD-L1 and CTLA-4, etc. PD-1/PD-L1 is the mainstream product in the market, accounting for % sales share globally in 2022.
Immune Checkpoint Inhibitors is widely used in various fields, such as Lung Cancer, Colorectal Cancer, Breast Cancer and Prostate Cancer, etc. Lung Cancer provides greatest supports to the Immune Checkpoint Inhibitors industry development. In 2022, global % sales of Immune Checkpoint Inhibitors went into Lung Cancer filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Immune Checkpoint Inhibitors market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bristol Myer Squibb
AstraZeneca
Merck
Roche / Genentech
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Segment by Type
PD-1/PD-L1
CTLA-4

Segment by Application


Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Immune Checkpoint Inhibitors market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Immune Checkpoint Inhibitors, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Immune Checkpoint Inhibitors industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Immune Checkpoint Inhibitors in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Immune Checkpoint Inhibitors introduction, etc. Immune Checkpoint Inhibitors Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Immune Checkpoint Inhibitors market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Immune Checkpoint Inhibitors Market Overview
1.1 Immune Checkpoint Inhibitors Product Overview
1.2 Immune Checkpoint Inhibitors Market Segment by Type
1.2.1 PD-1/PD-L1
1.2.2 CTLA-4
1.3 Global Immune Checkpoint Inhibitors Market Size by Type
1.3.1 Global Immune Checkpoint Inhibitors Market Size Overview by Type (2024-2034)
1.3.2 Global Immune Checkpoint Inhibitors Historic Market Size Review by Type (2024-2024)
1.3.3 Global Immune Checkpoint Inhibitors Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Type (2024-2024)
1.4.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific Immune Checkpoint Inhibitors Sales Breakdown by Type (2024-2024)
1.4.4 Latin America Immune Checkpoint Inhibitors Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa Immune Checkpoint Inhibitors Sales Breakdown by Type (2024-2024)
2 Global Immune Checkpoint Inhibitors Market Competition by Company
2.1 Global Top Players by Immune Checkpoint Inhibitors Sales (2024-2024)
2.2 Global Top Players by Immune Checkpoint Inhibitors Revenue (2024-2024)
2.3 Global Top Players by Immune Checkpoint Inhibitors Price (2024-2024)
2.4 Global Top Manufacturers Immune Checkpoint Inhibitors Manufacturing Base Distribution, Sales Area, Product Type
2.5 Immune Checkpoint Inhibitors Market Competitive Situation and Trends
2.5.1 Immune Checkpoint Inhibitors Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Immune Checkpoint Inhibitors Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2022)
2.7 Date of Key Manufacturers Enter into Immune Checkpoint Inhibitors Market
2.8 Key Manufacturers Immune Checkpoint Inhibitors Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Immune Checkpoint Inhibitors Status and Outlook by Region
3.1 Global Immune Checkpoint Inhibitors Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global Immune Checkpoint Inhibitors Historic Market Size by Region
3.2.1 Global Immune Checkpoint Inhibitors Sales in Volume by Region (2024-2024)
3.2.2 Global Immune Checkpoint Inhibitors Sales in Value by Region (2024-2024)
3.2.3 Global Immune Checkpoint Inhibitors Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global Immune Checkpoint Inhibitors Forecasted Market Size by Region
3.3.1 Global Immune Checkpoint Inhibitors Sales in Volume by Region (2024-2034)
3.3.2 Global Immune Checkpoint Inhibitors Sales in Value by Region (2024-2034)
3.3.3 Global Immune Checkpoint Inhibitors Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Immune Checkpoint Inhibitors by Application
4.1 Immune Checkpoint Inhibitors Market Segment by Application
4.1.1 Lung Cancer
4.1.2 Colorectal Cancer
4.1.3 Breast Cancer
4.1.4 Prostate Cancer
4.1.5 Melanoma
4.1.6 Blood Cancer
4.1.7 Other
4.2 Global Immune Checkpoint Inhibitors Market Size by Application
4.2.1 Global Immune Checkpoint Inhibitors Market Size Overview by Application (2024-2034)
4.2.2 Global Immune Checkpoint Inhibitors Historic Market Size Review by Application (2024-2024)
4.2.3 Global Immune Checkpoint Inhibitors Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Application (2024-2024)
4.3.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific Immune Checkpoint Inhibitors Sales Breakdown by Application (2024-2024)
4.3.4 Latin America Immune Checkpoint Inhibitors Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa Immune Checkpoint Inhibitors Sales Breakdown by Application (2024-2024)
5 North America Immune Checkpoint Inhibitors by Country
5.1 North America Immune Checkpoint Inhibitors Historic Market Size by Country
5.1.1 North America Immune Checkpoint Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2024)
5.1.3 North America Immune Checkpoint Inhibitors Sales in Value by Country (2024-2024)
5.2 North America Immune Checkpoint Inhibitors Forecasted Market Size by Country
5.2.1 North America Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2034)
5.2.2 North America Immune Checkpoint Inhibitors Sales in Value by Country (2024-2034)
6 Europe Immune Checkpoint Inhibitors by Country
6.1 Europe Immune Checkpoint Inhibitors Historic Market Size by Country
6.1.1 Europe Immune Checkpoint Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2024)
6.1.3 Europe Immune Checkpoint Inhibitors Sales in Value by Country (2024-2024)
6.2 Europe Immune Checkpoint Inhibitors Forecasted Market Size by Country
6.2.1 Europe Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2034)
6.2.2 Europe Immune Checkpoint Inhibitors Sales in Value by Country (2024-2034)
7 Asia-Pacific Immune Checkpoint Inhibitors by Region
7.1 Asia-Pacific Immune Checkpoint Inhibitors Historic Market Size by Region
7.1.1 Asia-Pacific Immune Checkpoint Inhibitors Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific Immune Checkpoint Inhibitors Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific Immune Checkpoint Inhibitors Sales in Value by Region (2024-2024)
7.2 Asia-Pacific Immune Checkpoint Inhibitors Forecasted Market Size by Region
7.2.1 Asia-Pacific Immune Checkpoint Inhibitors Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Immune Checkpoint Inhibitors Sales in Value by Region (2024-2034)
8 Latin America Immune Checkpoint Inhibitors by Country
8.1 Latin America Immune Checkpoint Inhibitors Historic Market Size by Country
8.1.1 Latin America Immune Checkpoint Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2024)
8.1.3 Latin America Immune Checkpoint Inhibitors Sales in Value by Country (2024-2024)
8.2 Latin America Immune Checkpoint Inhibitors Forecasted Market Size by Country
8.2.1 Latin America Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2034)
8.2.2 Latin America Immune Checkpoint Inhibitors Sales in Value by Country (2024-2034)
9 Middle East and Africa Immune Checkpoint Inhibitors by Country
9.1 Middle East and Africa Immune Checkpoint Inhibitors Historic Market Size by Country
9.1.1 Middle East and Africa Immune Checkpoint Inhibitors Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa Immune Checkpoint Inhibitors Sales in Value by Country (2024-2024)
9.2 Middle East and Africa Immune Checkpoint Inhibitors Forecasted Market Size by Country
9.2.1 Middle East and Africa Immune Checkpoint Inhibitors Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Immune Checkpoint Inhibitors Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Bristol Myer Squibb
10.1.1 Bristol Myer Squibb Company Information
10.1.2 Bristol Myer Squibb Introduction and Business Overview
10.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products Offered
10.1.5 Bristol Myer Squibb Recent Development
10.2 AstraZeneca
10.2.1 AstraZeneca Company Information
10.2.2 AstraZeneca Introduction and Business Overview
10.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.2.4 AstraZeneca Immune Checkpoint Inhibitors Products Offered
10.2.5 AstraZeneca Recent Development
10.3 Merck
10.3.1 Merck Company Information
10.3.2 Merck Introduction and Business Overview
10.3.3 Merck Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.3.4 Merck Immune Checkpoint Inhibitors Products Offered
10.3.5 Merck Recent Development
10.4 Roche / Genentech
10.4.1 Roche / Genentech Company Information
10.4.2 Roche / Genentech Introduction and Business Overview
10.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Roche / Genentech Immune Checkpoint Inhibitors Products Offered
10.4.5 Roche / Genentech Recent Development
10.5 Ono Pharmaceutical
10.5.1 Ono Pharmaceutical Company Information
10.5.2 Ono Pharmaceutical Introduction and Business Overview
10.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Ono Pharmaceutical Immune Checkpoint Inhibitors Products Offered
10.5.5 Ono Pharmaceutical Recent Development
10.6 Regeneron
10.6.1 Regeneron Company Information
10.6.2 Regeneron Introduction and Business Overview
10.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.6.4 Regeneron Immune Checkpoint Inhibitors Products Offered
10.6.5 Regeneron Recent Development
10.7 Innovent
10.7.1 Innovent Company Information
10.7.2 Innovent Introduction and Business Overview
10.7.3 Innovent Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Innovent Immune Checkpoint Inhibitors Products Offered
10.7.5 Innovent Recent Development
10.8 Hengrui Medicine
10.8.1 Hengrui Medicine Company Information
10.8.2 Hengrui Medicine Introduction and Business Overview
10.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.8.4 Hengrui Medicine Immune Checkpoint Inhibitors Products Offered
10.8.5 Hengrui Medicine Recent Development
10.9 Junshi Biosciences
10.9.1 Junshi Biosciences Company Information
10.9.2 Junshi Biosciences Introduction and Business Overview
10.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2024-2024)
10.9.4 Junshi Biosciences Immune Checkpoint Inhibitors Products Offered
10.9.5 Junshi Biosciences Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Immune Checkpoint Inhibitors Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Immune Checkpoint Inhibitors Industrial Chain Analysis
11.4 Immune Checkpoint Inhibitors Market Dynamics
11.4.1 Immune Checkpoint Inhibitors Industry Trends
11.4.2 Immune Checkpoint Inhibitors Market Drivers
11.4.3 Immune Checkpoint Inhibitors Market Challenges
11.4.4 Immune Checkpoint Inhibitors Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Immune Checkpoint Inhibitors Distributors
12.3 Immune Checkpoint Inhibitors Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of PD-1/PD-L1
Table 2. Major Company of CTLA-4
Table 3. Global Immune Checkpoint Inhibitors Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 4. Global Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (K Units)
Table 5. Global Immune Checkpoint Inhibitors Sales Market Share in Volume by Type (2024-2024)
Table 6. Global Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (US& Million)
Table 7. Global Immune Checkpoint Inhibitors Market Share in Value by Type (2024-2024)
Table 8. Global Immune Checkpoint Inhibitors Price by Type (2024-2024) & (USD/Unit)
Table 9. Global Immune Checkpoint Inhibitors Sales by Type (2024-2034) & (K Units)
Table 10. Global Immune Checkpoint Inhibitors Sales Market Share in Volume by Type (2024-2034)
Table 11. Global Immune Checkpoint Inhibitors Sales by Type (2024-2034) & (US$ Million)
Table 12. Global Immune Checkpoint Inhibitors Sales Market Share in Value by Type (2024-2034)
Table 13. Global Immune Checkpoint Inhibitors Price by Type (2024-2034) & (USD/Unit)
Table 14. North America Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (K Units)
Table 15. North America Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 16. Europe Immune Checkpoint Inhibitors Sales (K Units) by Type (2024-2024)
Table 17. Europe Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 18. Asia-Pacific Immune Checkpoint Inhibitors Sales (K Units) by Type (2024-2024)
Table 19. Asia-Pacific Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 20. Latin America Immune Checkpoint Inhibitors Sales (K Units) by Type (2024-2024)
Table 21. Latin America Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 22. Middle East and Africa Immune Checkpoint Inhibitors Sales (K Units) by Type (2024-2024)
Table 23. Middle East and Africa Immune Checkpoint Inhibitors Sales by Type (2024-2024) & (US$ Million)
Table 24. Global Immune Checkpoint Inhibitors Sales by Company (2024-2024) & (K Units)
Table 25. Global Immune Checkpoint Inhibitors Sales Share by Company (2024-2024)
Table 26. Global Immune Checkpoint Inhibitors Revenue by Company (2024-2024) & (US$ Million)
Table 27. Global Immune Checkpoint Inhibitors Revenue Share by Company (2024-2024)
Table 28. Global Market Immune Checkpoint Inhibitors Price by Company (2024-2024) & (USD/Unit)
Table 29. Global Immune Checkpoint Inhibitors Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 30. Global Immune Checkpoint Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 31. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2022)
Table 32. Date of Key Manufacturers Enter into Immune Checkpoint Inhibitors Market
Table 33. Key Manufacturers Immune Checkpoint Inhibitors Product Type
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Immune Checkpoint Inhibitors Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 36. Global Immune Checkpoint Inhibitors Sales by Region (2024-2024) & (K Units)
Table 37. Global Immune Checkpoint Inhibitors Sales Market Share in Volume by Region (2024-2024)
Table 38. Global Immune Checkpoint Inhibitors Sales by Region (2024-2024) & (US$ Million)
Table 39. Global Immune Checkpoint Inhibitors Sales Market Share in Value by Region (2024-2024)
Table 40. Global Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2024)
Table 41. Global Immune Checkpoint Inhibitors Sales by Region (2024-2034) & (K Units)
Table 42. Global Immune Checkpoint Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 43. Global Immune Checkpoint Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 44. Global Immune Checkpoint Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 45. Global Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2034)
Table 46. Global Immune Checkpoint Inhibitors Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 47. Global Immune Checkpoint Inhibitors Sales by Application (2024-2024) & (K Units)
Table 48. Global Immune Checkpoint Inhibitors Sales Market Share in Volume by Application (2024-2024)
Table 49. Global Immune Checkpoint Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 50. Global Immune Checkpoint Inhibitors Sales Market Share in Value by Application (2024-2024)
Table 51. Global Immune Checkpoint Inhibitors Price by Application (2024-2024) & (USD/Unit)
Table 52. Global Immune Checkpoint Inhibitors Sales by Application (2024-2034) & (K Units)
Table 53. Global Immune Checkpoint Inhibitors Sales Market Share in Volume by Application (2024-2034)
Table 54. Global Immune Checkpoint Inhibitors Sales by Application (2024-2034) & (US$ Million)
Table 55. Global Immune Checkpoint Inhibitors Sales Market Share in Value by Application (2024-2034)
Table 56. Global Immune Checkpoint Inhibitors Price by Application (2024-2034) & (USD/Unit)
Table 57. North America Immune Checkpoint Inhibitors Sales by Application (2024-2024) (K Units)
Table 58. North America Immune Checkpoint Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 59. Europe Immune Checkpoint Inhibitors Sales by Application (2024-2024) (K Units)
Table 60. Europe Immune Checkpoint Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 61. Asia-Pacific Immune Checkpoint Inhibitors Sales by Application (2024-2024) (K Units)
Table 62. Asia-Pacific Immune Checkpoint Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 63. Latin America Immune Checkpoint Inhibitors Sales by Application (2024-2024) (K Units)
Table 64. Latin America Immune Checkpoint Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 65. Middle East and Africa Immune Checkpoint Inhibitors Sales by Application (2024-2024) (K Units)
Table 66. Middle East and Africa Immune Checkpoint Inhibitors Sales by Application (2024-2024) & (US$ Million)
Table 67. North America Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (K Units)
Table 68. North America Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 69. North America Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 70. North America Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 71. North America Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (K Units)
Table 72. North America Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 73. North America Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 74. North America Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 75. Europe Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (K Units)
Table 76. Europe Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 77. Europe Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 78. Europe Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 79. Europe Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (K Units)
Table 80. Europe Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 81. Europe Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 82. Europe Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 83. Asia-Pacific Immune Checkpoint Inhibitors Sales by Region (2024-2024) & (K Units)
Table 84. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Volume by Region (2024-2024)
Table 85. Asia-Pacific Immune Checkpoint Inhibitors Sales by Region (2024-2024) & (US$ Million)
Table 86. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Value by Region (2024-2024)
Table 87. Asia-Pacific Immune Checkpoint Inhibitors Sales by Region (2024-2034) & (K Units)
Table 88. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Volume by Region (2024-2034)
Table 89. Asia-Pacific Immune Checkpoint Inhibitors Sales by Region (2024-2034) & (US$ Million)
Table 90. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Value by Region (2024-2034)
Table 91. Latin America Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (K Units)
Table 92. Latin America Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 93. Latin America Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 94. Latin America Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 95. Latin America Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (K Units)
Table 96. Latin America Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 97. Latin America Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 98. Latin America Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 99. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (K Units)
Table 100. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2024)
Table 101. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2024-2024) & (US$ Million)
Table 102. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2024)
Table 103. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (K Units)
Table 104. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share in Volume by Country (2024-2034)
Table 105. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2024-2034) & (US$ Million)
Table 106. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share in Value by Country (2024-2034)
Table 107. Bristol Myer Squibb Company Information
Table 108. Bristol Myer Squibb Introduction and Business Overview
Table 109. Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 110. Bristol Myer Squibb Immune Checkpoint Inhibitors Product
Table 111. Bristol Myer Squibb Recent Development
Table 112. AstraZeneca Company Information
Table 113. AstraZeneca Introduction and Business Overview
Table 114. AstraZeneca Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 115. AstraZeneca Immune Checkpoint Inhibitors Product
Table 116. AstraZeneca Recent Development
Table 117. Merck Company Information
Table 118. Merck Introduction and Business Overview
Table 119. Merck Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 120. Merck Immune Checkpoint Inhibitors Product
Table 121. Merck Recent Development
Table 122. Roche / Genentech Company Information
Table 123. Roche / Genentech Introduction and Business Overview
Table 124. Roche / Genentech Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 125. Roche / Genentech Immune Checkpoint Inhibitors Product
Table 126. Roche / Genentech Recent Development
Table 127. Ono Pharmaceutical Company Information
Table 128. Ono Pharmaceutical Introduction and Business Overview
Table 129. Ono Pharmaceutical Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 130. Ono Pharmaceutical Immune Checkpoint Inhibitors Product
Table 131. Ono Pharmaceutical Recent Development
Table 132. Regeneron Company Information
Table 133. Regeneron Introduction and Business Overview
Table 134. Regeneron Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 135. Regeneron Immune Checkpoint Inhibitors Product
Table 136. Regeneron Recent Development
Table 137. Innovent Company Information
Table 138. Innovent Introduction and Business Overview
Table 139. Innovent Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 140. Innovent Immune Checkpoint Inhibitors Product
Table 141. Innovent Recent Development
Table 142. Hengrui Medicine Company Information
Table 143. Hengrui Medicine Introduction and Business Overview
Table 144. Hengrui Medicine Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 145. Hengrui Medicine Immune Checkpoint Inhibitors Product
Table 146. Hengrui Medicine Recent Development
Table 147. Junshi Biosciences Company Information
Table 148. Junshi Biosciences Introduction and Business Overview
Table 149. Junshi Biosciences Immune Checkpoint Inhibitors Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 150. Junshi Biosciences Immune Checkpoint Inhibitors Product
Table 151. Junshi Biosciences Recent Development
Table 152. Key Raw Materials Lists
Table 153. Raw Materials Key Suppliers Lists
Table 154. Immune Checkpoint Inhibitors Market Trends
Table 155. Immune Checkpoint Inhibitors Market Drivers
Table 156. Immune Checkpoint Inhibitors Market Challenges
Table 157. Immune Checkpoint Inhibitors Market Restraints
Table 158. Immune Checkpoint Inhibitors Distributors List
Table 159. Immune Checkpoint Inhibitors Downstream Customers
Table 160. Research Programs/Design for This Report
Table 161. Key Data Information from Secondary Sources
Table 162. Key Data Information from Primary Sources
List of Figures
Figure 1. Immune Checkpoint Inhibitors Product Picture
Figure 2. Global Immune Checkpoint Inhibitors Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Immune Checkpoint Inhibitors Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global Immune Checkpoint Inhibitors Sales Status and Outlook (2024-2034) & (K Units)
Figure 5. Product Picture of PD-1/PD-L1
Figure 6. Global PD-1/PD-L1 Sales YoY Growth (2024-2034) & (K Units)
Figure 7. Product Picture of CTLA-4
Figure 8. Global CTLA-4 Sales YoY Growth (2024-2034) & (K Units)
Figure 9. Global Immune Checkpoint Inhibitors Sales by Type (2024-2034) & (US$ Million)
Figure 10. Global Immune Checkpoint Inhibitors Sales Market Share by Type in 2022 & 2034
Figure 11. North America Immune Checkpoint Inhibitors Sales Market Share in Volume by Type in 2022
Figure 12. North America Immune Checkpoint Inhibitors Sales Market Share in Value by Type in 2022
Figure 13. Europe Immune Checkpoint Inhibitors Sales Market Share in Volume by Type in 2022
Figure 14. Europe Immune Checkpoint Inhibitors Sales Market Share in Value by Type in 2022
Figure 15. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Volume by Type in 2022
Figure 16. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Value by Type in 2022
Figure 17. Latin America Immune Checkpoint Inhibitors Sales Market Share in Volume by Type in 2022
Figure 18. Latin America Immune Checkpoint Inhibitors Sales Market Share in Value by Type in 2022
Figure 19. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share in Volume by Type in 2022
Figure 20. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share in Value by Type in 2022
Figure 21. The 5 and 10 Largest Manufacturers in the World: Market Share by Immune Checkpoint Inhibitors Sales in 2022
Figure 22. The 5 and 10 Largest Manufacturers in the World: Market Share by Immune Checkpoint Inhibitors Revenue in 2022
Figure 23. Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 24. Product Picture of Lung Cancer
Figure 25. Global Lung Cancer Sales YoY Growth (2024-2034) & (K Units)
Figure 26. Product Picture of Colorectal Cancer
Figure 27. Global Colorectal Cancer Sales YoY Growth (2024-2034) & (K Units)
Figure 28. Product Picture of Breast Cancer
Figure 29. Global Breast Cancer Sales YoY Growth (2024-2034) & (K Units)
Figure 30. Product Picture of Prostate Cancer
Figure 31. Global Prostate Cancer Sales YoY Growth (2024-2034) & (K Units)
Figure 32. Product Picture of Melanoma
Figure 33. Global Melanoma Sales YoY Growth (2024-2034) & (K Units)
Figure 34. Product Picture of Blood Cancer
Figure 35. Global Blood Cancer Sales YoY Growth (2024-2034) & (K Units)
Figure 36. Product Picture of Other
Figure 37. Global Other Sales YoY Growth (2024-2034) & (K Units)
Figure 38. Global Immune Checkpoint Inhibitors Sales by Application (2024-2034) & (US$ Million)
Figure 39. Global Immune Checkpoint Inhibitors Sales Market Share by Application in 2022 & 2034
Figure 40. North America Immune Checkpoint Inhibitors Sales Market Share in Volume by Application in 2022
Figure 41. North America Immune Checkpoint Inhibitors Sales Market Share in Value by Application in 2022
Figure 42. Europe Immune Checkpoint Inhibitors Sales Market Share in Volume by Application in 2022
Figure 43. Europe Immune Checkpoint Inhibitors Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Immune Checkpoint Inhibitors Sales Market Share in Value by Application in 2022
Figure 46. Latin America Immune Checkpoint Inhibitors Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Immune Checkpoint Inhibitors Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Immune Checkpoint Inhibitors Manufacturing Cost Structure
Figure 51. Immune Checkpoint Inhibitors Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries